Quality of life scores · people who underwent a lower limb revascularisation
1 finding from 1 review
Intervention not reported
Total studies: 50 Total participants: 14,926 · people with chronic pain Interventions: duloxetine low dose (< 60 mg), standard dose (60 mg), and high dose (> 60 mg); milnacipran…
1 finding from 1 review
no estimate extracted
50 participants
GRADE not reported
Intervention not reported
Duloxetine high dose RCTs: 14 Participants: 3683 · people with chronic pain Interventions: duloxetine low dose (< 60 mg), standard dose (60 mg), and high dose (> 60 mg); milnacipran…
1 finding from 1 review
no estimate extracted
14 participants
Low
Intervention not reported
Duloxetine standard dose RCTs: 18 Participants: 4959 · people with chronic pain Interventions: duloxetine low dose (< 60 mg), standard dose (60 mg), and high dose (> 60 mg); milnacipran…
1 finding from 1 review
no estimate extracted
18 participants
Moderate
Intervention not reported
Milnacipran high dose RCTs: 2 Participants: 1670 · people with chronic pain Interventions: duloxetine low dose (< 60 mg), standard dose (60 mg), and high dose (> 60 mg); milnacipran…
1 finding from 1 review
no estimate extracted
2 participants
Low
Intervention not reported
Milnacipran standard dose RCTs: 4 Participants: 1866 · people with chronic pain Interventions: duloxetine low dose (< 60 mg), standard dose (60 mg), and high dose (> 60 mg); milnacipran…
1 finding from 1 review
no estimate extracted
4 participants
Moderate
Intervention not reported
Duloxetine low dose RCTs: 6 Participants: 1104 · people with chronic pain Interventions: duloxetine low dose (< 60 mg), standard dose (60 mg), and high dose (> 60 mg); milnacipran…
1 finding from 1 review
no estimate extracted
6 participants
Moderate
Clinician‐reported signs of eczema · people with eczema
1 finding from 1 review
Patient‐reported symptoms of eczema · people with eczema
1 finding from 1 review
Adverse effects: local · people with eczema
1 finding from 1 review
Systemic adverse events at · people with eczema
1 finding from 1 review
Circuit lifespana · AKI patients receiving CKRT
1 finding from 1 review
Death from any cause at day 28 of · AKI patients receiving CKRT
It is very uncertain whether long (> 20 cm) changes death from any cause at day 28 of compared with short (≤ 20 cm) catheter (very low certainty).
1 finding from 1 review
Recovery of kidney function · AKI patients receiving CKRT
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Vascular access complications · AKI patients receiving CKRT
Long (> 20 cm) may leads to lower vascular access complications compared with short (≤ 20 cm) catheter (low certainty).
1 finding from 1 review
Outcomes (4 to 12 weeks · the prevention of cardiovascular disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · the prevention of cardiovascular disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
CV Mortality · the prevention of cardiovascular disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Stroke · the prevention of cardiovascular disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
MI · the prevention of cardiovascular disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found